US20100159013A1 - flavored clay-based therapeutic composition - Google Patents
flavored clay-based therapeutic composition Download PDFInfo
- Publication number
- US20100159013A1 US20100159013A1 US12/733,172 US73317208A US2010159013A1 US 20100159013 A1 US20100159013 A1 US 20100159013A1 US 73317208 A US73317208 A US 73317208A US 2010159013 A1 US2010159013 A1 US 2010159013A1
- Authority
- US
- United States
- Prior art keywords
- composition according
- flavor
- composition
- weight
- encapsulated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/12—Magnesium silicate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- the present Application relates to a flavored pharmaceutical composition containing a smectite as active ingredient.
- the subject of the present invention is therefore a flavored therapeutic composition containing a clay as active ingredient, and characterized in that
- a composition according to the present invention can be used for the prevention and/or treatment of certain pathologies such as the symptomatic treatment of pain associated with oesogastroduodenal and colic conditions, acute and chronic diarrhoeas, coeliac disease.
- Smectites represent a particular family of clay in which dioctaedral species such as montmorillonite and beidellite, and trioctaedral species such as hectorite and saponite are found.
- the clay used according to the invention is a dioctahedral smectite.
- the dioctahedral smectite is a montmorillonite or a beidellite or a crystallographic structure intermediate between the two crystal-chemical poles: montmorillonite and beidellite.
- This intermediate crystallographic structure can be close to the montmorillonite pole and even very close to the montmorillonite pole; it can also be close to the beidellite pole and even very close to the beidellite pole.
- a smectite according to the invention is a montmorillonite or an intermediate structure close to the montmorillonite pole, and very preferably very close to the montmorillonite pole.
- the clay used is the smectite known as “diosmectite” and sold under the trade-mark Smecta®.
- the therapeutic composition according to the present invention comprises “a flavoring ingredient or composition”, called “flavor”.
- flavor as used in the present Application covers the flavoring ingredients or compositions usually used in the food industry, whether of natural or synthetic origin. It comprises single compounds or mixtures.
- the flavor is a hydrophobic liquid, soluble in organic solvents but only very weakly soluble in water.
- the flavor is characterized by a Hildebrand solubility parameter 8 less than 30 MPa 1/2 .
- the incompatibility with water of most of the flavors and perfumes can in fact be expressed by means of the Hildebrand solubility parameter which is in general less than 25 MPa 1/2 while the same parameter for water is 48 MPa 1/2 and for alkanes, 15-16 MPa 1/2 .
- This parameter gives a useful polarity scale correlated with a cohesive energy density of the molecules. For mixing to take place spontaneously, the difference in solubility of the molecules to be mixed must be kept to a minimum.
- the handbook of solubility parameters (Handbook of Solubility Parameters, A. F. M. Barton, CRC Press, Bocca Raton, 1991) gives a list of 8 values for a large number of chemical products but also recommended group-contribution methods allowing the 8 values for complex chemical structures to be calculated.
- the flavor is in a liquid, volatile or labile form, with a log P comprised within the range ⁇ 2 to 7, and very preferably, from 2 to 6.
- composition according to the present invention comprises, as flavor, natural extracts, essential oils or a mixture thereof.
- traditional flavors can be mentioned such as liquorice, exotic fruits, red fruits, extracts of citrus fruits such as lime, lemon, orange, grapefruit, or mandarin oils or coffee, tea, mint, cocoa, vanilla/caramel or essential oils from herbs and spices, or also flavors known as “modern” such as coca-cola, green tea, caramel custard.
- a composition according to the invention comprises at least one encapsulated flavor different from vanilla.
- the flavors are preferably chosen from the traditional flavors such as liquorice, exotic fruits, red fruits, extracts of citrus fruits, vanilla/caramel/chocolate but also flavors known as “modern” such coca-cola, green tea, caramel custard.
- the flavor is chosen from vanilla/caramel/chocolate flavors and extracts of citrus fruits and very preferably, vanilla/caramel/chocolate and orange, lemon, grapefruit or clementine.
- the flavor is a mixture of flavors, and very preferably, a mixture of vanilla and orange flavors.
- the flavor can be mixed with solvents, adjuvants, additives and/or other substances, for example those usually used in the flavor and/or food industry.
- the flavor according to the present invention is preferably encapsulated in a glassy matrix (encapsulation matrix) of carbohydrate(s).
- Any sugar or sugar derivative which can be processed by extrusion techniques can be used as constituent(s) of the encapsulation matrix, in order to form a dry extruded solid.
- suitable constituents can be chosen from the following products: sucrose, glucose, lactose, levulose, fructose, maltose, ribose, dextrose, isomalt, sorbitol, mannitol, xylitol, lactitol, maltitol, pentatol, arabinose, pentose, xylose, galactose, hydrogenated starch hydrolysates, maltodextrin, Stabilite (trade name; origin: SPI Polyols, USA), agar, carrageenan, other gums, polydextrose and the derivatives and mixtures thereof.
- maltodextrin or mixtures of maltodextrin and at least one product chosen from: sucrose, glucose, lactose, levulose, maltose, fructose, isomalt, sorbitol, mannitol, xylitol, lactitol, maltitol and hydrogenated starch hydrolysates are used.
- the matrix is constituted by maltodextrin or a mixture of maltodextrin and at least one product chosen from: sucrose, maltose, isomalt, maltitol and hydrogenated starch hydrolysates.
- the matrix is constituted by maltodextrin and sucrose.
- the maltodextrin has a dextrose equivalent (DE) greater than 5 and less than 20.
- DE dextrose equivalent
- An emulsifier such as lecithin, and/or a plasticizer, typically water, can be added to the mixture if necessary.
- the flavored product or the flavored composition according to the invention, which are extruded, can be prepared by any standard method.
- the methods described in U.S. Pat. Nos. 4,610,890 and 4,707,367, the content of which is incorporated by way of reference, are suitable for supplying encapsulated flavors as used in the present invention.
- the flavor is present in a proportion of at least 10% by weight expressed as dry matter, with respect to the total weight (expressed as dry matter) of the encapsulation matrix, and preferably in a proportion comprised between 15 and 35%.
- a composition according to the invention comprises preferably 70 to 90% by weight of active ingredient, and very preferably from 75 to 85%, with respect to the total weight of the composition.
- a composition according to the invention comprises 0.1 to 3% by weight of encapsulated flavor with respect to the total weight of the composition, and very preferably 0.3 to 2.5%. Also very preferably, a composition according to the invention comprises 0.5 to 2% by weight of encapsulated flavour with respect to the total weight of the composition.
- a therapeutic composition according to the present invention can be presented in different solid forms such as for example powders, granules, tablets or capsules.
- Appropriate solid supports can be, for example, talc, sugars, lactose, dextrin, gelatin, cellulose and its esters.
- composition according to the present invention there can also be also other additives such as colouring agents, sweetening agents, lubricants, glidants.
- a composition according to the present invention can also contain minerals.
- the colouring agent(s) used according to the present invention can be any type of colouring agents usually used in the food and/or the pharmaceutical industries.
- sweetening agents the following can be mentioned: saccharin, aspartame, maltodextrin, monosaccharides such as fructose or glucose, disaccharides such as saccharose.
- talc can be mentioned for example.
- glidant agents saccharose can be mentioned.
- the mineral contribution can for example consist of the addition of metal salts such as aluminium or magnesium salts such as aluminium hydroxide, magnesium carbonate.
- compositions according to the invention are chosen, among others, according to its pharmaceutical form and the pathology to be treated.
- composition as defined above is administered by the oral route.
- the daily administration dose is the usual recommended dose for this product.
- the smectite known as “diosmectite”
- it can be administered at a maximum daily dose of 18 g/day.
- a syrup is prepared from maltodextrin, sucrose, water and flavor.
- the mixture is then heated to 123° C. in order to reduce the moisture content of the syrup.
- the emulsifier is mixed with the concentrated syrup under high shear conditions in order to form a uniform melt.
- the melt is then extruded under a pressure of 2 ⁇ 10 5 Pa through an extrusion die plate with holes of 0.8 mm diameter in a cold solvent for chilling and breaking of the extrudates.
- Example 1 is reproduced by using a vanilla extract (ex Firmenich) instead of the orange flavor.
- Example 1 is reproduced by using a caramel flavor (ex Firmenich) instead of the orange flavor.
- compositions below are prepared by gently mixing all the substances together in the proportions indicated, until they are dispersed in a homogenous fashion. In the table below, all the quantities are expressed in mg.
- Example Example Example Example Ingredients 4a 4b 4c Diosmectite 3000 3000 3000 Encapsulated orange flavor — — 10 (flavor prepared according to Example 1) 1 Encapsulated vanilla flavor 50 50 (flavor prepared according to Example 2) 2 Encapsulated caramel ® flavor 10 — — (flavor prepared according to Example 3) 3 Soluble saccharine + hydrated 700 710 700 glucose Water 100 100 100 1 ex Firmenich, ref. 501289 TD 0990B; 2 ex Firmenich, ref. 501465 TD1591; 3 ex Firmenich, ref. 501403 TD 1094
- composition according to the invention is measured both as regards the organoleptic characteristics of the flavor and for its inertia vis-à-vis the clay.
- the stability of the organoleptic characteristics of the flavor is established by testers (panel of 7 experts) on the basis of a number of criteria (sugary, fruity, acidic, bitterness, etc.) over a period of at least 6 months.
- the flavor shows no deterioration in the presence of the clay over this same period.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Silicates, Zeolites, And Molecular Sieves (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fats And Perfumes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cosmetics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Confectionery (AREA)
Abstract
Description
- This application is the U.S. National Stage filing of International Application No. PCT/FR2008/001185, filed Aug. 12, 2008, which claims priority to EP 07291005.2, filed Aug. 13, 2007, the disclosures of which are hereby incorporated by reference in their entirety.
- The present Application relates to a flavored pharmaceutical composition containing a smectite as active ingredient.
- A therapeutic composition based on smectite known as “diosmectite” exists and is sold under the trade-mark Smecta®. But due to the particular taste of the clay which certain patients and children in particular can sometimes find unpleasant, the problem was therefore to find a novel composition which is flavored and the taste of which remains predominant vis-à-vis the taste of the clay. In order to solve this problem, the Applicant proposes a novel flavored pharmaceutical composition based on smectite and as defined below.
- The subject of the present invention is therefore a flavored therapeutic composition containing a clay as active ingredient, and characterized in that
-
- the clay is a dioctahedral smectite; and
- the flavored is encapsulated.
- A composition according to the present invention can be used for the prevention and/or treatment of certain pathologies such as the symptomatic treatment of pain associated with oesogastroduodenal and colic conditions, acute and chronic diarrhoeas, coeliac disease.
- Smectites represent a particular family of clay in which dioctaedral species such as montmorillonite and beidellite, and trioctaedral species such as hectorite and saponite are found.
- The clay used according to the invention is a dioctahedral smectite. Preferably, the dioctahedral smectite is a montmorillonite or a beidellite or a crystallographic structure intermediate between the two crystal-chemical poles: montmorillonite and beidellite. This intermediate crystallographic structure can be close to the montmorillonite pole and even very close to the montmorillonite pole; it can also be close to the beidellite pole and even very close to the beidellite pole. Preferably, a smectite according to the invention is a montmorillonite or an intermediate structure close to the montmorillonite pole, and very preferably very close to the montmorillonite pole.
- Also preferably, the clay used is the smectite known as “diosmectite” and sold under the trade-mark Smecta®.
- The therapeutic composition according to the present invention comprises “a flavoring ingredient or composition”, called “flavor”. The term “flavor” as used in the present Application covers the flavoring ingredients or compositions usually used in the food industry, whether of natural or synthetic origin. It comprises single compounds or mixtures.
- Specific examples of such compounds can be found in the literature, such as for example in Fenaroli's Handbook of Flavor Ingredients, 1975, CRC Press; Synthetic Food Adjuncts, 1947, M. B. Jacobs, published by Van Nostrand; or Perfume and Flavor Chemicals, 1969, S. Arctander, Montclair, N.J. (USA).
- These compounds are well known to a person skilled in the art in the field of flavoring or aromatizing consumer products, i.e. traditionally flavored consumer products to which an odour, a flavor or a taste has been added, or consumer products the taste of which has been modified.
- Preferably, the flavor is a hydrophobic liquid, soluble in organic solvents but only very weakly soluble in water.
- Very preferably, the flavor is characterized by a Hildebrand solubility parameter 8 less than 30 MPa1/2. The incompatibility with water of most of the flavors and perfumes can in fact be expressed by means of the Hildebrand solubility parameter which is in general less than 25 MPa1/2 while the same parameter for water is 48 MPa1/2 and for alkanes, 15-16 MPa1/2. This parameter gives a useful polarity scale correlated with a cohesive energy density of the molecules. For mixing to take place spontaneously, the difference in solubility of the molecules to be mixed must be kept to a minimum. The handbook of solubility parameters (Handbook of Solubility Parameters, A. F. M. Barton, CRC Press, Bocca Raton, 1991) gives a list of 8 values for a large number of chemical products but also recommended group-contribution methods allowing the 8 values for complex chemical structures to be calculated.
- Also preferably, the flavor is in a liquid, volatile or labile form, with a log P comprised within the range −2 to 7, and very preferably, from 2 to 6.
- Also in a preferred fashion, a composition according to the present invention comprises, as flavor, natural extracts, essential oils or a mixture thereof.
- As a suitable flavor, traditional flavors can be mentioned such as liquorice, exotic fruits, red fruits, extracts of citrus fruits such as lime, lemon, orange, grapefruit, or mandarin oils or coffee, tea, mint, cocoa, vanilla/caramel or essential oils from herbs and spices, or also flavors known as “modern” such as coca-cola, green tea, caramel custard.
- Preferably, a composition according to the invention comprises at least one encapsulated flavor different from vanilla.
- The flavors are preferably chosen from the traditional flavors such as liquorice, exotic fruits, red fruits, extracts of citrus fruits, vanilla/caramel/chocolate but also flavors known as “modern” such coca-cola, green tea, caramel custard.
- Preferably, the flavor is chosen from vanilla/caramel/chocolate flavors and extracts of citrus fruits and very preferably, vanilla/caramel/chocolate and orange, lemon, grapefruit or clementine.
- Also in a preferred fashion, the flavor is a mixture of flavors, and very preferably, a mixture of vanilla and orange flavors.
- The flavor can be mixed with solvents, adjuvants, additives and/or other substances, for example those usually used in the flavor and/or food industry.
- The flavor according to the present invention is preferably encapsulated in a glassy matrix (encapsulation matrix) of carbohydrate(s).
- Any sugar or sugar derivative which can be processed by extrusion techniques can be used as constituent(s) of the encapsulation matrix, in order to form a dry extruded solid. Particular examples of suitable constituents can be chosen from the following products: sucrose, glucose, lactose, levulose, fructose, maltose, ribose, dextrose, isomalt, sorbitol, mannitol, xylitol, lactitol, maltitol, pentatol, arabinose, pentose, xylose, galactose, hydrogenated starch hydrolysates, maltodextrin, Stabilite (trade name; origin: SPI Polyols, USA), agar, carrageenan, other gums, polydextrose and the derivatives and mixtures thereof.
- Preferably, maltodextrin or mixtures of maltodextrin and at least one product chosen from: sucrose, glucose, lactose, levulose, maltose, fructose, isomalt, sorbitol, mannitol, xylitol, lactitol, maltitol and hydrogenated starch hydrolysates are used. Very preferably, the matrix is constituted by maltodextrin or a mixture of maltodextrin and at least one product chosen from: sucrose, maltose, isomalt, maltitol and hydrogenated starch hydrolysates. Also very preferably, the matrix is constituted by maltodextrin and sucrose.
- Preferably, the maltodextrin has a dextrose equivalent (DE) greater than 5 and less than 20.
- An emulsifier such as lecithin, and/or a plasticizer, typically water, can be added to the mixture if necessary.
- The flavored product or the flavored composition according to the invention, which are extruded, can be prepared by any standard method. For example, the methods described in U.S. Pat. Nos. 4,610,890 and 4,707,367, the content of which is incorporated by way of reference, are suitable for supplying encapsulated flavors as used in the present invention.
- Also preferably, the flavor is present in a proportion of at least 10% by weight expressed as dry matter, with respect to the total weight (expressed as dry matter) of the encapsulation matrix, and preferably in a proportion comprised between 15 and 35%.
- A composition according to the invention comprises preferably 70 to 90% by weight of active ingredient, and very preferably from 75 to 85%, with respect to the total weight of the composition.
- Also preferably, a composition according to the invention comprises 0.1 to 3% by weight of encapsulated flavor with respect to the total weight of the composition, and very preferably 0.3 to 2.5%. Also very preferably, a composition according to the invention comprises 0.5 to 2% by weight of encapsulated flavour with respect to the total weight of the composition.
- A therapeutic composition according to the present invention can be presented in different solid forms such as for example powders, granules, tablets or capsules. Appropriate solid supports can be, for example, talc, sugars, lactose, dextrin, gelatin, cellulose and its esters.
- In a therapeutic composition according to the present invention, there can also be also other additives such as colouring agents, sweetening agents, lubricants, glidants. A composition according to the present invention can also contain minerals.
- The colouring agent(s) used according to the present invention can be any type of colouring agents usually used in the food and/or the pharmaceutical industries. Among the sweetening agents, the following can be mentioned: saccharin, aspartame, maltodextrin, monosaccharides such as fructose or glucose, disaccharides such as saccharose. Among the lubricating agents, talc can be mentioned for example. Among the glidant agents, saccharose can be mentioned.
- The mineral contribution can for example consist of the addition of metal salts such as aluminium or magnesium salts such as aluminium hydroxide, magnesium carbonate.
- The administration method for a composition according to the invention is chosen, among others, according to its pharmaceutical form and the pathology to be treated. Preferably, the composition as defined above is administered by the oral route.
- The daily administration dose is the usual recommended dose for this product. In the particular case of the smectite known as “diosmectite”, it can be administered at a maximum daily dose of 18 g/day.
- Unless defined otherwise, all the technical and scientific terms used here have the same meaning as that usually understood by an ordinary specialist in the field to which this invention belongs.
- A syrup is prepared from maltodextrin, sucrose, water and flavor. The mixture is then heated to 123° C. in order to reduce the moisture content of the syrup. Then, the emulsifier is mixed with the concentrated syrup under high shear conditions in order to form a uniform melt. The melt is then extruded under a pressure of 2×105 Pa through an extrusion die plate with holes of 0.8 mm diameter in a cold solvent for chilling and breaking of the extrudates.
-
Ingredients in grams (g) % dry matter Maltodextrin 18DE 1505 44.55 Sucrose 1505 44.55 Cold-pressed oil of Valencia orange 350 10.36 Soya lecithin1) 18 0.54 Water 400 — Total 100.00 1)origin: Central Soya, Strong Wayne, Indiana, USA - Example 1 is reproduced by using a vanilla extract (ex Firmenich) instead of the orange flavor.
- Example 1 is reproduced by using a caramel flavor (ex Firmenich) instead of the orange flavor.
- The compositions below are prepared by gently mixing all the substances together in the proportions indicated, until they are dispersed in a homogenous fashion. In the table below, all the quantities are expressed in mg.
-
Example Example Example Ingredients 4a 4b 4c Diosmectite 3000 3000 3000 Encapsulated orange flavor — — 10 (flavor prepared according to Example 1) 1 Encapsulated vanilla flavor 50 50 50 (flavor prepared according to Example 2) 2 Encapsulated caramel ® flavor 10 — — (flavor prepared according to Example 3) 3 Soluble saccharine + hydrated 700 710 700 glucose Water 100 100 100 1 ex Firmenich, ref. 501289 TD 0990B; 2 ex Firmenich, ref. 501465 TD1591; 3 ex Firmenich, ref. 501403 TD 1094 - Clay being a stable product naturally, the stability of a composition according to the invention is measured both as regards the organoleptic characteristics of the flavor and for its inertia vis-à-vis the clay.
- The stability of the organoleptic characteristics of the flavor is established by testers (panel of 7 experts) on the basis of a number of criteria (sugary, fruity, acidic, bitterness, etc.) over a period of at least 6 months.
- Moreover, it is noted that the flavor shows no deterioration in the presence of the clay over this same period.
Claims (28)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07291005A EP2025332A1 (en) | 2007-08-13 | 2007-08-13 | Clay-based aromatised therapeutic composition |
EP07291005.2 | 2007-08-13 | ||
PCT/FR2008/001185 WO2009056703A1 (en) | 2007-08-13 | 2008-08-12 | Flavoured clay-based therapeutic composition |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2008/001185 A-371-Of-International WO2009056703A1 (en) | 2007-08-13 | 2008-08-12 | Flavoured clay-based therapeutic composition |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/178,445 Continuation US9056055B2 (en) | 2007-08-13 | 2014-02-12 | Flavoured clay-based therapeutic composition |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100159013A1 true US20100159013A1 (en) | 2010-06-24 |
Family
ID=39052728
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/733,172 Abandoned US20100159013A1 (en) | 2007-08-13 | 2008-08-12 | flavored clay-based therapeutic composition |
US14/178,445 Expired - Fee Related US9056055B2 (en) | 2007-08-13 | 2014-02-12 | Flavoured clay-based therapeutic composition |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/178,445 Expired - Fee Related US9056055B2 (en) | 2007-08-13 | 2014-02-12 | Flavoured clay-based therapeutic composition |
Country Status (27)
Country | Link |
---|---|
US (2) | US20100159013A1 (en) |
EP (3) | EP2025332A1 (en) |
JP (2) | JP5670189B2 (en) |
KR (2) | KR101503957B1 (en) |
CN (2) | CN101778622A (en) |
AR (2) | AR067929A1 (en) |
BR (1) | BRPI0814979A2 (en) |
CA (1) | CA2696062C (en) |
CL (1) | CL2008002366A1 (en) |
DK (1) | DK2194968T3 (en) |
EA (1) | EA017118B1 (en) |
ES (2) | ES2582871T3 (en) |
GE (1) | GEP20125539B (en) |
HK (2) | HK1143956A1 (en) |
HU (1) | HUE029713T2 (en) |
MA (1) | MA31678B1 (en) |
ME (1) | ME00975B (en) |
MX (1) | MX2010001533A (en) |
NO (1) | NO20100114L (en) |
PE (1) | PE20090939A1 (en) |
PL (2) | PL2710998T3 (en) |
PT (2) | PT2194968E (en) |
SA (1) | SA08290496B1 (en) |
TN (1) | TN2010000058A1 (en) |
TW (2) | TWI511734B (en) |
UA (1) | UA97408C2 (en) |
WO (1) | WO2009056703A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITUA20162277A1 (en) * | 2016-04-04 | 2017-10-04 | Chemists Res Srl | Composition comprising diosmectite |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2025332A1 (en) * | 2007-08-13 | 2009-02-18 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Clay-based aromatised therapeutic composition |
FR2952814B1 (en) * | 2009-11-23 | 2013-07-19 | Ephyla Sas | COMPOSITION COMPRISING A COMPLEXES OF ORGANICALLY MODIFIED PHYLLOSILICATES GENERATING EMULSIONS OIL IN WATER POSSIBLY COLD |
JP2014503552A (en) | 2011-01-12 | 2014-02-13 | ソーフト イタリア エスピーエー | Corneal delivery of cross-linking agents by iontophoresis and related ophthalmic compositions for the treatment of keratoconus |
CN105902625A (en) * | 2016-05-26 | 2016-08-31 | 朱胜利 | Method for taking infantile antidiarrheic |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4610890A (en) * | 1984-07-16 | 1986-09-09 | Sunkist Growers, Inc. | Preparation of solid essential oil flavor composition |
US4707367A (en) * | 1984-07-16 | 1987-11-17 | Sunkist Growers, Inc. | Solid essential oil flavor composition |
US6187351B1 (en) * | 1993-04-16 | 2001-02-13 | Mccormick & Company, Inc. | Encapsulation compositions |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH064530B2 (en) * | 1985-02-23 | 1994-01-19 | 日本化薬株式会社 | Hydrophilic base |
US5288497A (en) * | 1985-05-01 | 1994-02-22 | The University Of Utah | Compositions of oral dissolvable medicaments |
FR2770778B1 (en) * | 1997-11-12 | 2000-05-26 | Investigations Therapeutiques | COMPOSITION FOR THE TREATMENT OF ACUTE GASTROENTERITIS, MANUFACTURING METHOD THEREOF AND TREATMENT SOLUTION OBTAINED FROM THIS COMPOSITION |
KR20030050958A (en) * | 2001-12-20 | 2003-06-25 | 송우영 | External bacteriocidal composition comprising dioctaheral smectite as effective ingredient |
US8334007B2 (en) * | 2003-03-19 | 2012-12-18 | Firmenich Sa | Continuous process for the incorporation of a flavor or fragrance ingredient or composition into a carbohydrate matrix |
CN100340235C (en) * | 2004-05-21 | 2007-10-03 | 山东绿叶制药有限公司 | Montmorillonite dispersed tablet and preparation technique thereof |
EP1627573A1 (en) * | 2004-08-20 | 2006-02-22 | Firmenich Sa | A process for the incorporation of a flavor or fragrance ingredient or composition into a carbohydrate matrix |
JP2006083071A (en) * | 2004-09-14 | 2006-03-30 | Takasago Internatl Corp | Solid preparation for fragrant cosmetic |
WO2007051427A1 (en) * | 2005-11-04 | 2007-05-10 | Zhejiang Hailisheng Pharmaceutical Limited Co. | Modified montmorillonite, method for preparing the same and use thereof |
FR2901360A1 (en) | 2006-05-16 | 2007-11-23 | Horiba Abx Sas Soc Par Actions | PACKAGING DEVICE FOR BIOLOGICAL ANALYSIS |
EP2025332A1 (en) * | 2007-08-13 | 2009-02-18 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Clay-based aromatised therapeutic composition |
-
2007
- 2007-08-13 EP EP07291005A patent/EP2025332A1/en not_active Withdrawn
-
2008
- 2008-07-23 TW TW103138915A patent/TWI511734B/en active
- 2008-07-23 TW TW097127881A patent/TWI519303B/en active
- 2008-08-10 SA SA08290496A patent/SA08290496B1/en unknown
- 2008-08-11 PE PE2008001364A patent/PE20090939A1/en active IP Right Grant
- 2008-08-12 JP JP2010520608A patent/JP5670189B2/en not_active Expired - Fee Related
- 2008-08-12 PL PL13002485.4T patent/PL2710998T3/en unknown
- 2008-08-12 MX MX2010001533A patent/MX2010001533A/en active IP Right Grant
- 2008-08-12 ES ES13002485.4T patent/ES2582871T3/en active Active
- 2008-08-12 ES ES08843692T patent/ES2421379T3/en active Active
- 2008-08-12 WO PCT/FR2008/001185 patent/WO2009056703A1/en active Application Filing
- 2008-08-12 GE GEAP200811722A patent/GEP20125539B/en unknown
- 2008-08-12 EA EA201070257A patent/EA017118B1/en unknown
- 2008-08-12 BR BRPI0814979-8A2A patent/BRPI0814979A2/en not_active Application Discontinuation
- 2008-08-12 KR KR1020107005450A patent/KR101503957B1/en active IP Right Grant
- 2008-08-12 PL PL08843692T patent/PL2194968T3/en unknown
- 2008-08-12 UA UAA201002684A patent/UA97408C2/en unknown
- 2008-08-12 CL CL2008002366A patent/CL2008002366A1/en unknown
- 2008-08-12 KR KR1020147030942A patent/KR20140133617A/en not_active Application Discontinuation
- 2008-08-12 CN CN200880103357A patent/CN101778622A/en active Pending
- 2008-08-12 US US12/733,172 patent/US20100159013A1/en not_active Abandoned
- 2008-08-12 PT PT88436928T patent/PT2194968E/en unknown
- 2008-08-12 ME MEP-2010-20A patent/ME00975B/en unknown
- 2008-08-12 HU HUE13002485A patent/HUE029713T2/en unknown
- 2008-08-12 DK DK08843692.8T patent/DK2194968T3/en active
- 2008-08-12 PT PT130024854T patent/PT2710998T/en unknown
- 2008-08-12 EP EP13002485.4A patent/EP2710998B1/en not_active Not-in-force
- 2008-08-12 EP EP08843692.8A patent/EP2194968B1/en active Active
- 2008-08-12 CN CN201410349941.6A patent/CN104173371A/en active Pending
- 2008-08-12 CA CA2696062A patent/CA2696062C/en not_active Expired - Fee Related
- 2008-08-13 AR ARP080103533A patent/AR067929A1/en not_active Application Discontinuation
-
2010
- 2010-01-22 NO NO20100114A patent/NO20100114L/en not_active Application Discontinuation
- 2010-02-05 MA MA32592A patent/MA31678B1/en unknown
- 2010-02-05 TN TNP2010000058A patent/TN2010000058A1/en unknown
- 2010-11-12 HK HK10110577.8A patent/HK1143956A1/en unknown
-
2014
- 2014-02-12 US US14/178,445 patent/US9056055B2/en not_active Expired - Fee Related
- 2014-08-13 JP JP2014164964A patent/JP2014208715A/en active Pending
- 2014-09-26 HK HK14109703.3A patent/HK1196271A1/en not_active IP Right Cessation
-
2018
- 2018-11-23 AR ARP180103440A patent/AR114148A2/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4610890A (en) * | 1984-07-16 | 1986-09-09 | Sunkist Growers, Inc. | Preparation of solid essential oil flavor composition |
US4707367A (en) * | 1984-07-16 | 1987-11-17 | Sunkist Growers, Inc. | Solid essential oil flavor composition |
US6187351B1 (en) * | 1993-04-16 | 2001-02-13 | Mccormick & Company, Inc. | Encapsulation compositions |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITUA20162277A1 (en) * | 2016-04-04 | 2017-10-04 | Chemists Res Srl | Composition comprising diosmectite |
EP3228318A1 (en) * | 2016-04-04 | 2017-10-11 | Chemist's Research S.r.l. | Composition comprising diosmectite |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9056055B2 (en) | Flavoured clay-based therapeutic composition | |
RU2391863C2 (en) | Polyphenol containing composition and isomaltose preparation | |
US20090208602A1 (en) | Confectionery aroma containing products | |
US2714083A (en) | Appetite satient | |
KR102304605B1 (en) | Composition for improvement of memory and cognition ability, prevention, delay, treatment or improvement of Alzheimer's disease, comprising extracts of Chionanthus retusa Lindl. & Paxton leaf | |
KR100625508B1 (en) | Compositions inhibiting a decrease in bone weight and a decrease in bone salt content in disuse muscle atrophy | |
JP2017519046A (en) | Sweetness receptor antagonist composition | |
JP5048238B2 (en) | Oral formulation containing dried walnut extract | |
KR100907201B1 (en) | Liquid medicine for internal use | |
JP2004107285A (en) | Agent for ameliorating dysphagia | |
EP3181150A1 (en) | Pharmaceutical compositions | |
EP1594370A1 (en) | Use of d-tagatose for improving aroma taste | |
DE69729729T2 (en) | MEDICINAL PRODUCT FOR USE IN THE MOUTH | |
JP6835396B2 (en) | Composition for reducing blood glucose concentration, reducing blood hemoglobin A1c amount, or increasing blood HDL-cholesterol level | |
JP7368858B2 (en) | Biofilm formation inhibitor | |
JP4889846B2 (en) | High-sweetness sweetener-containing composition | |
WO2020261538A1 (en) | Composition for lowering blood pressure | |
JP2002212085A (en) | Uric acid value-reducing agent | |
US20070292534A1 (en) | Antacid and breath freshening composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: IPSEN PHARMA S.A.S.,FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BARRA, JEROME;LE HAZIF, DENIS;SIGNING DATES FROM 20100120 TO 20100125;REEL/FRAME:024019/0024 Owner name: FIRMENICH S.A.,SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BARRA, JEROME;LE HAZIF, DENIS;SIGNING DATES FROM 20100120 TO 20100125;REEL/FRAME:024019/0024 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: IPSEN PHARMA S.A.S., FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BARRA, JEROME;LE HAZIF, DENIS;SIGNING DATES FROM 20100120 TO 20100125;REEL/FRAME:033602/0642 Owner name: FIRMENICH S.A., SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BARRA, JEROME;LE HAZIF, DENIS;SIGNING DATES FROM 20100120 TO 20100125;REEL/FRAME:033602/0642 |